PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Riveiro Barciela M, Gevers TJG, Terziroli Beretta-Piccoli B, Londoño MC, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode M, Schulze K.
Kocheise L, et al. Among authors: lohse aw.
Front Immunol. 2024 Jan 10;14:1326078. doi: 10.3389/fimmu.2023.1326078. eCollection 2023.
Front Immunol. 2024.
PMID: 38268921
Free PMC article.